
News|Articles|January 10, 2013
Canagliflozin may not be good for the heart, FDA says
Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.
Advertisement
dagfgaf
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























